Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NeoGenomicsNEO -0.73%63 EBITDA Margin % is 9.33% as of Jun. 2026, which is 19% above its 10-year median of 7.83. GuruFocus rates NEO with a GF Score™ of 63/100 and a GF Value™ of $16.09 (Fairly Valued). The stock has 6 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, NeoGenomics ranks worse than 54.19% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. NeoGenomics's EBITDA for the
three
months ended in Jun. 2026 was $18.8 Mil. NeoGenomics's Revenue for the
three
months ended in Jun. 2026 was $201.7 Mil. Therefore, NeoGenomics's EBITDA margin for the quarter that ended in Jun. 2026 was 9.33%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
NeoGenomics EBITDA Margin % Related Terms
NeoGenomics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for NeoGenomics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NEO vs WGS, CDNA, PSNL: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, NeoGenomics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NeoGenomics EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, NeoGenomics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where NeoGenomics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NeoGenomics (NEO) has a EBITDA Margin % of 9.33% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on NeoGenomics and its competitors. This is 19% above median its historical median of 7.83. According to the industry distribution chart, NeoGenomics ranks #110 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 54.2%.
Is NeoGenomics' EBITDA Margin % too high?
NeoGenomics' current EBITDA Margin % of 9.33% is 19% above median its 10-year median of 7.83. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.00. NeoGenomics' value of 9.33% is 86.6% above this industry median. Based on the distribution chart, NeoGenomics ranks #110 out of 203 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, NeoGenomics has a GF Score™ of 63/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does NeoGenomics' EBITDA Margin % compare to WGS and CDNA?
According to the Medical Diagnostics & Research industry distribution chart, NeoGenomics ranks #110 out of 203 companies for EBITDA Margin %. This places NeoGenomics in the lower half of its industry. The industry median EBITDA Margin % is 5.00. NeoGenomics' value of 9.33% is 86.6% above this benchmark. While the company's 10-year median is 7.83 vs. the industry median of 5.00, NeoGenomics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.00, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NeoGenomics's current EBITDA Margin % of 9.33% is 86.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on NeoGenomics and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NeoGenomics's current EBITDA Margin % is 9.33%, which is 19% above median its own 10-year median of 7.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeoGenomics stock overvalued right now?
Based on GuruFocus' analysis, NeoGenomics (NEO) is currently considered Fairly Valued. The stock's GF Value™ is $16.09, compared to a current price of $16.43 — trading 2.1% above its estimated fair value. The current EBITDA Margin % is 9.33%, which is 19% above median its 10-year median of 7.83 and 86.6% above the Medical Diagnostics & Research industry median of 5.00. NeoGenomics' overall GF Score™ is 63/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For NeoGenomics (NEO), the current EBITDA Margin % is 9.33% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NeoGenomics (NEO) Overvalued in 2026?
Based on GuruFocus' analysis, NeoGenomics stock appears to be overvalued.
The current stock price of $16.43 is trading 2.1% above its estimated GF Value™ of $16.09.
GuruFocus considers NeoGenomics to be Fairly Valued.
Key valuation signals for NEO:
EBITDA Margin %: 9.33% (19% above median its 10-year median of 7.83)
GF Value™: $16.09 vs. price of $16.43 (2.1% above fair value)
Industry Position: 86.6% above the Medical Diagnostics & Research median (#110 of 203)
No single metric tells the full story. See the NEO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
63GF Score
Get the complete analysis for NEO
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NEO has been successfully added to your 
